Skip to content

Can a 12-week Yoga, Triorigin smile mudra meditation, and diet program improve hormones and well-being in women with PCOS aged 20 to 35 years

Integrative Approach to PCOS: Effects of Yoga, Triorigin Smile Mudra and Meditation, and Dietary Interventions on Endocrine, Metabolic, and Psychological Health - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109116
Enrollment
90
Registered
2026-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Yoga with dietary supplementation: Participants will receive a structured yoga intervention including loosening practices, asanas, pranayama, relaxation, and meditation along with stand

Sponsors

Pragya Daga
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Women aged 20 to 35 years diagnosed with polycystic ovary syndrome (PCOS) based on Rotterdam criteria (meeting at least two of the following: oligo/amenorrhea, clinical or biochemical hyperandrogenism, or polycystic ovarian morphology), confirmed by a qualified gynecologist. Participants should be willing to provide written informed consent and comply with the study protocol.

Exclusion criteria

Exclusion criteria: Participants currently on hormonal therapy or oral contraceptives, pregnant or planning pregnancy, or those who have taken insulin-sensitizing agents in the past 6 weeks will be excluded. Individuals with uncontrolled or clinically significant thyroid disorders, hyperprolactinemia, severe psychiatric disorders, or other major systemic illnesses will be excluded. Participants with regular engagement in structured yoga practice or high-intensity physical activity, as well as those with regular smoking or alcohol consumption, will also be excluded.

Design outcomes

Primary

MeasureTime frame
Serum Anti-M llerian Hormone (AMH) levels (ng/mL)Timepoint: Baseline and 12 weeks.

Secondary

MeasureTime frame
Hormonal Outcomes 1)Serum testosterone levels (ng/dL). 2)Fasting insulin levels (pmol/L). 3)LH, FSH, estrogen, progesterone levels. 4)Prolactin and cortisol levels 5)Thyroid profile 6)Free Androgen Index (FAI) 7)Sex Hormone Binding Globulin (SHBG)Timepoint: Baseline and 12 weeks.;Metabolic Outcomes 1)Fasting blood glucose and HbA1c 2)Insulin resistance (HOMA-IR) 3)Lipid profile. 4)Liver Function Test. 5)Waist-to-hip ratio.Timepoint: Baseline and 12 weeks.;Micronutrient Parameters 1)Vitamin D levels 2)Vitamin B12 levels 3)Iron profileTimepoint: Baseline and 12 weeks.;Psychological Parameters 1)Depression, Anxiety, and Stress (DASS-21) 2)Quality of life (PCOSQOL) 3)Life satisfaction (SWLS) 4)Psychological well-being (Oxford Happiness Questionnaire)Timepoint: Baseline and 12 weeks.;Behavioral Parameters 1)Eating behavior (self-reported food diary) 2)Sleep quality (Pittsburgh Sleep Quality Index PSQI)Timepoint: Baseline and 12 weeks.;Qualitative Outcomes 1)Participant interviews 2)Observational assessments during intervention sessionsTimepoint: Baseline and 12 weeks.

Countries

India

Contacts

Public ContactDr. Bharathi Dhevi V R

SVYASA Deemed to be University

pragya4daga@gmail.com9674687345

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026